- Conditions
- Follicular Lymphoma
- Interventions
- Rituximab, Neo Vax, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 70
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Solid Tumors, Adult
- Interventions
- VB10.NEO
- Biological
- Lead sponsor
- Nykode Therapeutics ASA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- San Francisco, California • New Haven, Connecticut • Louisville, Kentucky + 2 more
- Conditions
- HPV Vaccination Intent
- Interventions
- Default-style LLM chatbot, Conversational-style LLM chatbot, Public health informational materials
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 930 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Colorectal Neoplasms
- Interventions
- GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Fluoropyrimidine plus leucovorin, Bevacizumab
- Drug
- Lead sponsor
- Seattle Project Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 43
- States / cities
- Gilbert, Arizona • Springdale, Arkansas • Los Angeles, California + 36 more
- Conditions
- Recurrent Glioblastoma
- Interventions
- pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1), RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)
- Biological
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- HCC
- Interventions
- GNOS-PV02, INO-9012, Pembrolizumab, CELLECTRA®2000 EP Device
- Biological · Drug · Device
- Lead sponsor
- Geneos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • New York, New York
- Conditions
- Glioblastoma
- Interventions
- Radiation Therapy, Personalized NeoAntigen Peptides, Pembrolizumab, Temozolomide, Poly-ICLC
- Radiation · Biological · Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Carboplatin, Computed Tomography, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Nab-paclitaxel, Personalized Synthetic Long Peptide Vaccine, Poly ICLC, Sacituzumab Govitecan, Tremelimumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 30
- States / cities
- Orange, California • Sacramento, California • Aurora, Colorado + 22 more
- Conditions
- Individuality, Healthy, Asthma, Immune System and Related Disorders
- Interventions
- Pneumococcal Vaccination
- Biological
- Lead sponsor
- Michigan State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- East Lansing, Michigan
- Conditions
- Metastatic Colorectal Cancer, Stage II/III Colon Cancer
- Interventions
- blood collection for research (next generation sequencing [NGS]), blood collection for research (HLA typing), blood collection for research (circulating tumor DNA [ctDNA])
- Procedure
- Lead sponsor
- Gritstone bio, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Miami, Florida • Tamarac, Florida • East Brunswick, New Jersey + 3 more
- Conditions
- Kidney Cancer
- Interventions
- NeoVax, Ipilimumab
- Drug
- Lead sponsor
- Patrick Ott, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Interventions
- PANDA-VAC, Pembrolizumab
- Biological · Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2033
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Cervical Cancer, Anal Cancer, Penile Cancer
- Interventions
- Personalized Chatbot Intervention, Non-Personalized Chatbot Intervention, No Chatbot Control
- Behavioral
- Lead sponsor
- University of Maryland, College Park
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 456 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- College Park, Maryland
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Paclitaxel, Carboplatin, Pembrolizumab, Doxorubicin, Cyclophosphamide, Personalized cancer vaccine (PCV), AB248, pVAC tools neoantigen prediction algorithm, poly-ICLC
- Drug · Biological · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Follicular Lymphoma
- Interventions
- Personalized tumor vaccine, Poly ICLC, Nivolumab, Peripheral blood draws, Leukapheresis, Rituximab, Biopsy
- Biological · Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Cutaneous Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Urothelial Carcinoma, Renal Cell Carcinoma
- Interventions
- GEN-009 Adjuvanted Vaccine, Nivolumab, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Genocea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 11
- States / cities
- La Jolla, California • Santa Monica, California • Aurora, Colorado + 8 more
- Conditions
- Prostate Cancer
- Interventions
- PGV-001, Poly-ICLC, CDX-301
- Biological
- Lead sponsor
- Ashutosh Kumar Tewari
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pancreatic Cancer
- Interventions
- Atezolizumab, RO7198457, mFOLFIRINOX
- Drug · Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Vaccination
- Interventions
- Vaccine Information Video Dissemination
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 507 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Vaccine Hesitancy, COVID-19 Testing, Community Health Workers
- Interventions
- Community Health Worker led curriculum
- Behavioral
- Lead sponsor
- Charles Drew University of Medicine and Science
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Metastatic Melanoma
- Interventions
- NEO-PV-01, Nivolumab, Adjuvant, APX005M, ipilimumab
- Biological · Other
- Lead sponsor
- BioNTech US Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 4 more
- Conditions
- Cancer
- Interventions
- Personalized Synthetic Long Peptide Vaccine
- Biological
- Lead sponsor
- Jaime Leandro Foundation for Therapeutic Cancer Vaccines
- Other
- Eligibility
- 12 Years and older
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Cancer of Gastrointestinal Tract
- Interventions
- personalized vaccine, Nivolumab
- Biological · Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Smoldering Plasma Cell Myeloma
- Interventions
- Biopsy Specimen Radiography, Lenalidomide, Vaccine Therapy
- Procedure · Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas